We caught up with Ernest Choy (Cardiff University, Cardiff, UK) to discuss olokizumab as a novel rheumatoid arthritis (RA) treatment option. The symposia ‘Taking the High Road: Olokizumab as a Novel Rheumatoid Arthritis (RA) Treatment Option’ was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
1.What is the rationale for the use of olokizumab in patients with rheumatoid arthritis?(0:12)
2.What clinical evidence supports the efficacy and safety of olokizumab in this indication?(0:38)
3.What are the advantages of olokizumab compared with other available IL-6 inhibitors?(1:28)
4.Which patients are most likely to benefit from olokizumab and in whom is it contraindicated?(1:56)
5.What will be the next steps in the clinical development of olokizumab in rheumatoid arthritis?(2:48)
Disclosures: Professor Choy has received speaker and consultancy fees from R-Pharm.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).
Share this Video
Related Videos In Rheumatoid Arthritis
Roy Fleischmann, ACR 2021: Efficacy and Safety of Olokizumab plus Methotrexate in a Placebo and Active Controlled Study
Dr Roy Fleischmann (University of Texas Southwestern Medical Center, Dallas, TX, USA) discusses the results from the phase 3, head-to-head, randomized, placebo-controlled clinical trial investigating olokizumab in patients with active rheumatoid arthritis inadequately controlled with methotrexate, with a comparator arm of adalimumab. This information is brought to you by Touch Medical Media and is not […]
Roy Fleischmann, ACR 2021: Safety and Efficacy of Tofacitinib vs TNF Inhibitors in ORAL Surveillance
It was a pleasure to speak with Dr Roy Fleischmann (University of Texas Southwestern Medical Center, Dallas, TX, USA) about ORAL Surveillance (NCT02092467). Mandated by the FDA, due to observed increases in lipids and malignancies in patients with RA treated with tofacitinib, this study was designed to investigate the relative risk of tofacitinib compared to […]
Gilles Boire, ACR 2021: A Mindfulness-Based Program to Improve PROs in patients with Rheumatoid Arthritis
It was a pleasure to discuss with Prof. Gilles Boire (Université de Sherbrooke, Québec, Canada) the recent pilot study in which a Mindfulness-Based Stress Reduction (MBSR) program was offered to patients with controlled rheumatoid arthritis but elevated negative PROs. This information is brought to you by Touch Medical Media and is not sponsored by, nor […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!